LAMEA Oncology Drugs Market Size, Share & Industry Trends Analysis Report By Indication, By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy and Hormonal Therapy), By Country and Growth Forecast, 2023

List of Tables

The Latin America, Middle East and Africa Oncology Drugs Market would witness market growth of 11.1% CAGR during the forecast period (2023-2030).

The biosimilar oncology drugs are experiencing rapid growth. Biosimilars are highly similar versions of authorized biologic drugs and offer a more cost-effective alternative to branded therapies. This trend contributes to increased accessibility of cancer treatments, especially in regions where healthcare affordability is a significant concern. Integrating digital health technologies, including telemedicine, wearable devices, and real-time data analytics, is transforming cancer care. These technologies facilitate remote patient monitoring, personalized treatment adjustments, and the collection of real-world evidence, providing valuable insights for drug development and improving patient outcomes.

Lung cancer remains a significant health challenge, and the market is witnessing a surge in the development of novel therapeutics for both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Targeted therapies such as EGFR and immune checkpoint inhibitors have shown promise in improving survival rates for lung cancer patients. Hematology-oncology is witnessing remarkable progress, particularly in treating hematological malignancies like lymphoma, leukemia, and multiple myeloma. Immunotherapies, including CAR-T cell therapies, have demonstrated unprecedented success in certain blood cancers, offering new hope for patients with limited treatment options.

The LAMEA region comprises countries with diverse populations and healthcare systems. Variations in healthcare infrastructure, access to medical services, and regulatory environments can signficantly impact the market differently in each country. Some countries in the LAMEA region have been increasing investments in healthcare infrastructure, including cancer treatment facilities and research centers. The need for targeted therapies, which can offer more precise and less toxic treatment options, may increase with the aging population. These aspects will boost the market growth in the coming years.

The Brazil region dominated the LAMEA Oncology Drugs Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $5,878.3 million by 2030. The Argentina region is showcasing a CAGR of 12.2% during (2023 - 2030). Additionally, The UAE region would register a CAGR of 10.8% during (2023 - 2030).

Based on Indication, the market is segmented into Breast Cancer, Prostate Cancer, Lung Cancer, Stomach Cancer, Colorectal Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer and Other Cancer. Based on Drug Class Type, the market is segmented into Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy and Hormonal Therapy. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Amgen, Inc., Astellas Pharma, Inc., AstraZeneca PLC, Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Novartis AG, Merck & Co., Inc. and Pfizer Inc.

Scope of the Study

Market Segments covered in the Report:

By Indication

Breast Cancer
Prostate Cancer
Lung Cancer
Stomach Cancer
Colorectal Cancer
Liver Cancer
Esophagus Cancer
Cervical Cancer
Kidney Cancer
Bladder Cancer
Other Cancer

By Drug Class Type

Targeted Therapy
Immunotherapy (Biologic Therapy)
Chemotherapy
Hormonal Therapy

By Country

Brazil
Argentina
UAE
Saudi Arabia
South Africa
Nigeria
Rest of LAMEA

Companies Profiled

AbbVie, Inc.
Amgen, Inc.
Astellas Pharma, Inc.
AstraZeneca PLC
Bristol Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Johnson & Johnson
Novartis AG
Merck & Co., Inc.
Pfizer Inc.

Unique Offerings from KBV Research

Exhaustive coverage
Highest number of market tables and figures
Subscription based model available
Guaranteed best price
Assured post sales research support with 10% customization free

Chapter 1. Market Scope & Methodology

1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
- 1.4.1 LAMEA Oncology Drugs Market, by Indication
- 1.4.2 LAMEA Oncology Drugs Market, by Drug Class Type
- 1.4.3 LAMEA Oncology Drugs Market, by Country
1.5 Methodology for the research

Chapter 2. Market at a Glance

2.1 Key Highlights

Chapter 3. Market Overview

3.1 Introduction
- 3.1.1 Overview
  - 3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
- 3.2.1 Market Drivers
- 3.2.2 Market Restraints

Chapter 4. Competition Analysis - Global

4.1 KBV Cardinal Matrix
4.2 Recent Industry Wide Strategic Developments
- 4.2.1 Partnerships, Collaborations and Agreements
- 4.2.2 Product Launches and Product Expansions
- 4.2.3 Acquisition and Mergers
4.3 Top Winning Strategies
- 4.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
- 4.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements : 2019, Mar - 2023, Nov) Leading Players
4.4 Porter's Five Forces Analysis

Chapter 5. LAMEA Oncology Drugs Market by Indication

5.1 LAMEA Breast Cancer Market by Country
5.2 LAMEA Prostate Cancer Market by Country
5.3 LAMEA Lung Cancer Market by Country
5.4 LAMEA Stomach Cancer Market by Country
5.5 LAMEA Colorectal Cancer Market by Country
5.6 LAMEA Liver Cancer Market by Country
5.7 LAMEA Esophagus Cancer Market by Country
5.8 LAMEA Cervical Cancer Market by Country
5.9 LAMEA Kidney Cancer Market by Country
5.10. LAMEA Bladder Cancer Market by Country
5.11 LAMEA Other Cancer Market by Country

Chapter 6. LAMEA Oncology Drugs Market by Drug Class Type

6.1 LAMEA Targeted Therapy Market by Country
6.2 LAMEA Immunotherapy (Biologic Therapy) Market by Country
6.3 LAMEA Chemotherapy Market by Country
6.4 LAMEA Hormonal Therapy Market by Country

Chapter 7. LAMEA Oncology Drugs Market by Country

7.1 Brazil Oncology Drugs Market
- 7.1.1 Brazil Oncology Drugs Market by Indication
- 7.1.2 Brazil Oncology Drugs Market by Drug Class Type
7.2 Argentina Oncology Drugs Market
- 7.2.1 Argentina Oncology Drugs Market by Indication
- 7.2.2 Argentina Oncology Drugs Market by Drug Class Type
7.3 UAE Oncology Drugs Market
- 7.3.1 UAE Oncology Drugs Market by Indication
- 7.3.2 UAE Oncology Drugs Market by Drug Class Type
7.4 Saudi Arabia Oncology Drugs Market
- 7.4.1 Saudi Arabia Oncology Drugs Market by Indication
- 7.4.2 Saudi Arabia Oncology Drugs Market by Drug Class Type
7.5 South Africa Oncology Drugs Market
- 7.5.1 South Africa Oncology Drugs Market by Indication
- 7.5.2 South Africa Oncology Drugs Market by Drug Class Type
7.6 Nigeria Oncology Drugs Market
- 7.6.1 Nigeria Oncology Drugs Market by Indication
- 7.6.2 Nigeria Oncology Drugs Market by Drug Class Type
7.7 Rest of LAMEA Oncology Drugs Market
- 7.7.1 Rest of LAMEA Oncology Drugs Market by Indication
- 7.7.2 Rest of LAMEA Oncology Drugs Market by Drug Class Type

Chapter 8. Company Profiles

8.1 AbbVie, Inc.
- 8.1.1 Company Overview
- 8.1.2 Financial Analysis
- 8.1.3 Regional Analysis
- 8.1.4 Research & Development Expense
- 8.1.5 Recent strategies and developments:
  - 8.1.5.1 Partnerships, Collaborations, and Agreements:
  - 8.1.5.2 Acquisition and Mergers:
- 8.1.6 SWOT Analysis
8.2 Amgen, Inc.
- 8.2.1 Company Overview
- 8.2.2 Financial Analysis
- 8.2.3 Regional Analysis
- 8.2.4 Research & Development Expenses
- 8.2.5 Recent strategies and developments:
  - 8.2.5.1 Acquisition and Mergers:
- 8.2.6 SWOT Analysis
8.3 Astellas Pharma, Inc.
- 8.3.1 Company Overview
- 8.3.2 Financial Analysis
- 8.3.3 Regional Analysis
- 8.3.4 Research & Development Expense
- 8.3.5 Recent strategies and developments:
  - 8.3.5.1 Partnerships, Collaborations, and Agreements:
  - 8.3.5.2 Acquisition and Mergers:
- 8.3.6 SWOT Analysis
8.4 AstraZeneca PLC
- 8.4.1 Company Overview
- 8.4.2 Financial Analysis
- 8.4.3 Regional Analysis
- 8.4.4 Research & Development Expenses
- 8.4.5 Recent strategies and developments:
  - 8.4.5.1 Partnerships, Collaborations, and Agreements:
  - 8.4.5.2 Product Launches and Product Expansions:
- 8.4.6 SWOT Analysis
8.5 Bristol Myers Squibb Company
- 8.5.1 Company Overview
- 8.5.2 Financial Analysis
- 8.5.3 Regional Analysis
- 8.5.4 Research & Development Expenses
- 8.5.5 Recent strategies and developments:
  - 8.5.5.1 Partnerships, Collaborations, and Agreements:
  - 8.5.5.2 Product Launches and Product Expansions:
  - 8.5.5.3 Acquisition and Mergers:
- 8.5.6 SWOT Analysis
8.6 F. Hoffmann-La Roche Ltd.
- 8.6.1 Company Overview
- 8.6.2 Financial Analysis
- 8.6.3 Segmental and Regional Analysis
- 8.6.4 Research & Development Expense
- 8.6.5 Recent strategies and developments:
  - 8.6.5.1 Partnerships, Collaborations, and Agreements:
  - 8.6.5.2 Product Launches and Product Expansions:
  - 8.6.5.3 Acquisition and Mergers:
- 8.6.6 SWOT Analysis
8.7 Johnson & Johnson
- 8.7.1 Company Overview
- 8.7.2 Financial Analysis
- 8.7.3 Segmental & Regional Analysis
- 8.7.4 Research & Development Expenses
- 8.7.5 Recent strategies and developments:
  - 8.7.5.1 Partnerships, Collaborations, and Agreements:
  - 8.7.5.2 Acquisition and Mergers:
- 8.7.6 SWOT Analysis
8.8 Novartis AG
- 8.8.1 Company Overview
- 8.8.2 Financial Analysis
- 8.8.3 Segmental and Regional Analysis
- 8.8.4 Research & Development Expense
- 8.8.5 Recent strategies and developments:
  - 8.8.5.1 Partnerships, Collaborations, and Agreements:
- 8.8.6 SWOT Analysis
8.9 Merck & Co., Inc.
- 8.9.1 Company Overview
- 8.9.2 Financial Analysis
- 8.9.3 Segmental and Regional Analysis
- 8.9.4 Research & Development Expenses
- 8.9.5 Recent strategies and developments:
  - 8.9.5.1 Partnerships, Collaborations, and Agreements:
  - 8.9.5.2 Acquisition and Mergers:
- 8.9.6 SWOT Analysis
8.10. Pfizer, Inc.
- 8.10.1 Company Overview
- 8.10.2 Financial Analysis
- 8.10.3 Regional & Segmental Analysis
- 8.10.4 Research & Development Expense
- 8.10.5 Recent strategies and developments:
  - 8.10.5.1 Partnerships, Collaborations, and Agreements:
- 8.10.6 SWOT Analysis

LIST OF TABLES

TABLE 1 LAMEA Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 2 LAMEA Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 3 Partnerships, Collaborations and Agreements- Oncology Drugs Market
TABLE 4 Product Launches And Product Expansions- Oncology Drugs Market
TABLE 5 Acquisition and Mergers- Oncology Drugs Market
TABLE 6 LAMEA Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 7 LAMEA Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 8 LAMEA Breast Cancer Market by Country, 2019 - 2022, USD Million
TABLE 9 LAMEA Breast Cancer Market by Country, 2023 - 2030, USD Million
TABLE 10 LAMEA Prostate Cancer Market by Country, 2019 - 2022, USD Million
TABLE 11 LAMEA Prostate Cancer Market by Country, 2023 - 2030, USD Million
TABLE 12 LAMEA Lung Cancer Market by Country, 2019 - 2022, USD Million
TABLE 13 LAMEA Lung Cancer Market by Country, 2023 - 2030, USD Million
TABLE 14 LAMEA Stomach Cancer Market by Country, 2019 - 2022, USD Million
TABLE 15 LAMEA Stomach Cancer Market by Country, 2023 - 2030, USD Million
TABLE 16 LAMEA Colorectal Cancer Market by Country, 2019 - 2022, USD Million
TABLE 17 LAMEA Colorectal Cancer Market by Country, 2023 - 2030, USD Million
TABLE 18 LAMEA Liver Cancer Market by Country, 2019 - 2022, USD Million
TABLE 19 LAMEA Liver Cancer Market by Country, 2023 - 2030, USD Million
TABLE 20 LAMEA Esophagus Cancer Market by Country, 2019 - 2022, USD Million
TABLE 21 LAMEA Esophagus Cancer Market by Country, 2023 - 2030, USD Million
TABLE 22 LAMEA Cervical Cancer Market by Country, 2019 - 2022, USD Million
TABLE 23 LAMEA Cervical Cancer Market by Country, 2023 - 2030, USD Million
TABLE 24 LAMEA Kidney Cancer Market by Country, 2019 - 2022, USD Million
TABLE 25 LAMEA Kidney Cancer Market by Country, 2023 - 2030, USD Million
TABLE 26 LAMEA Bladder Cancer Market by Country, 2019 - 2022, USD Million
TABLE 27 LAMEA Bladder Cancer Market by Country, 2023 - 2030, USD Million
TABLE 28 LAMEA Other Cancer Market by Country, 2019 - 2022, USD Million
TABLE 29 LAMEA Other Cancer Market by Country, 2023 - 2030, USD Million
TABLE 30 LAMEA Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 31 LAMEA Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 32 LAMEA Targeted Therapy Market by Country, 2019 - 2022, USD Million
TABLE 33 LAMEA Targeted Therapy Market by Country, 2023 - 2030, USD Million
TABLE 34 LAMEA Immunotherapy (Biologic Therapy) Market by Country, 2019 - 2022, USD Million
TABLE 35 LAMEA Immunotherapy (Biologic Therapy) Market by Country, 2023 - 2030, USD Million
TABLE 36 LAMEA Chemotherapy Market by Country, 2019 - 2022, USD Million
TABLE 37 LAMEA Chemotherapy Market by Country, 2023 - 2030, USD Million
TABLE 38 LAMEA Hormonal Therapy Market by Country, 2019 - 2022, USD Million
TABLE 39 LAMEA Hormonal Therapy Market by Country, 2023 - 2030, USD Million
TABLE 40 LAMEA Oncology Drugs Market by Country, 2019 - 2022, USD Million
TABLE 41 LAMEA Oncology Drugs Market by Country, 2023 - 2030, USD Million
TABLE 42 Brazil Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 43 Brazil Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 44 Brazil Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 45 Brazil Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 46 Brazil Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 47 Brazil Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 48 Argentina Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 49 Argentina Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 50 Argentina Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 51 Argentina Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 52 Argentina Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 53 Argentina Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 54 UAE Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 55 UAE Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 56 UAE Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 57 UAE Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 58 UAE Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 59 UAE Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 60 Saudi Arabia Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 61 Saudi Arabia Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 62 Saudi Arabia Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 63 Saudi Arabia Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 64 Saudi Arabia Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 65 Saudi Arabia Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 66 South Africa Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 67 South Africa Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 68 South Africa Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 69 South Africa Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 70 South Africa Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 71 South Africa Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 72 Nigeria Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 73 Nigeria Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 74 Nigeria Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 75 Nigeria Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 76 Nigeria Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 77 Nigeria Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 78 Rest of LAMEA Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 79 Rest of LAMEA Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 80 Rest of LAMEA Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 81 Rest of LAMEA Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 82 Rest of LAMEA Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 83 Rest of LAMEA Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 84 Key information - AbbVie, Inc.
TABLE 85 Key Information - Amgen, Inc.
TABLE 86 key information - Astellas Pharma, Inc.
TABLE 87 KEY INFORMATION - AstraZeneca PLC
TABLE 88 Key Information - Bristol Myers Squibb Company
TABLE 89 Key Information - F. Hoffmann-La Roche Ltd.
TABLE 90 Key Information - Johnson & Johnson
TABLE 91 Key Information - Novartis AG
TABLE 92 Key Information - Merck & Co., Inc.
TABLE 93 Key Information - Pfizer, Inc.

LAMEA Oncology Drugs Market Size, Share & Industry Trends Analysis Report By Indication, By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy and Hormonal Therapy), By Country and Growth Forecast, 2023 - 2030

Description

Table of Contents